In analyses adjusted for time-varying medical comorbidities, repeat testosterone testing, and intensity of PSA monitoring, and that followed men for a median of 3.0 years, we observed that in men with low testosterone levels and normal PSA levels at baseline, testosterone treatment was not associated with increased incidence of aggressive or any prostate cancer compared with untreated men. Here, KLK3 is linked to prostate cancer.